DOCSLIB.ORG

6Th International Workshop 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
6Th International Workshop 2020 Contents Welcome Message ...................................................................2 Organizing Committee .............................................................4 Floor Plan .................................................................................7 Agenda .....................................................................................8 Scientific Program ..................................................................12 Dec.19th (Sat.) Â 601 ..............................................................................12 Â 603 ..............................................................................54 Â Young Doctor Session / Oral Presentation ..............104 Dec.20th (Sun.) Â 601 ..............................................................................92 Â 603 ............................................................................104 Â Young Doctor Session / Oral Presentation ..............104 Official Sponsors ..................................................................136 Welcome Message Dear olleagues and Frends Welcome to the 6th nternatonal Worksho on ynecologc ncology o the Asan Socet o necologc ncolog (AS Worsho 2020) n Taan As the resdent o ASO, cordall nvte ou to the 6th Interna�onal Work- sho on ynecologc ncology o ASO, hch ll e held on Decemer 19th and 20th 2020 in CHANG YUNG-FA FOUNDATION Interna�onal Conven�on enter ae awan. AS as estalished leaders o aanese and Korean gynecologists in considera�on of the need for an Asian regional society dedicated to gynecologic cancer, and held its first mee�ng in Seoul in 2008. At present, gynecological oncology socie�es from 11 countries and regions have par�ci- pated, and it has become a truly unified organiza�on. Six biennial mee�ngs and five interna�onal worshos have een held to date however ths ASGO Workshop 2020 in Taiwan will be the first time for the congress to be held outsde o aan and orea. hs means that ths orsho ll propel ASGO out of its founders' zone, Japan and Korea, and begin to truly branch out across Asia. he develoment o surgcal technues and ne treatments n recent ears s remarale and e must learn and acquire them without delay. Let the exchange of knowledge and experience with our Asan colleagues e a smol o the AS Worsho 2020 AS Worshop 2020 ll arml elcome ou th numerous scentfic rograms as ell as traditonal awanese culture. We sncerel loo orward to meetng ou at the 6th nternatonal Worsho on necologc ncolog o the Asan Socet o necologc ncolog n 2020. Sncerel ours Daisuke Aoki, M.D., Ph.D. he Presdent o Asan Socet o necologc ncolog 2 Dear olleagues On behalf of the organizing committee, we are honored to cordially invite you to par�cipate in the 6th Interna�onal Workshop on Gyneco- logc ncology o AS (AS Worksho 2020) hch ll e held on Decemer 19th 20th n AN NFA FOUNDATION nternatonal onventon enter, aei, aan. Due to the COD19 andemc ASGO Workshop 2020 will be hosted in hybrid mee�ng. ASGO Workshop has been contribu�ng to the research, preven�on and treatment o gynecologcal cancer. Snce commenced n 2008, ASO has made tremendous rogress roviding unified comrehensve medical and surgical care to women with reproduc�ve tract cancers from diagnosis to comple�on of treatment. This year we will have speeches on topics covering in a variety of fields from dis�n- guished seaers n Asa and all o the orld to discuss the er latest advances n necologcal ncolog treatment and care. This is the first �me ASGO Workshop is held outside of Japan and Korea. We believe that ASGO Workshop 2020 will certainly be one of the most valuable �me for all the par�cipants. Your out- standing contribu�on and par�cipa�on will be crucial to the success of the conference. We sin- cerely look forward to gree�ng you at the 6th Interna�onal Workshop on Gynecologic Oncology n ae. Sncerel ours Chih-Ming Ho, M.D.,Ph.D. AS Worsho 2020 Organizing Commi�ee Chair TA Presdent 3 Organizing Committee ASGO WORKSHOP Executive committee members Presdent Dasue Ao (aan) Secretar eneral Yusue oayash (aan) Presdentlect reasurer aeWeon m (orea) mmedate Past Presdent eeSug u (orea) Council members Andr Androno (ndonesa) Presdent Dasue Ao (aan) DuSoo ae (orea) eera hatla (nda) Karen han (ongong) Eren Domngo (Phlnes) Presdentlect reasurer aeWeon m (orea) Seungheol m (orea) Secretar eneral Yusue oayash (aan) Suresh umarasamy (Malaysa) Masa Manda (aan) mmedate Past Presdent eeSug u (orea) Dad SP an (Sngaore) Kungahng Wang (aan) demch Watar (aan) Saraan Wlala (haland) Yang ang (hna) Rongu ang (hna) 4 Nominating committee members Shngo Fu (aan) Toshharu amura (aan) Sooneom ang (orea) Ikuo onsh (aan) ooun am (orea) eeSug u (orea) Scientific Program Committee Kungahng Wanghar (aan) nghang hangce har (aan) hengYang hou (aan) Soonen uang (aan) WenShung ou (aan) ao n (aan) Pengu Wang (aan) Musen u (aan) ungheng a (aan) WenFang heng (aan) anShung eh (aan) hensng u (aan) FuShng u (aan) Tze-Ho Chen (aan) Taau nomoto (aan) mo shma (aan) Yong Man m (orea) ae Weon m (orea) 5 TAGO Presdent hhMng o (atha eneral ostal) Execu�ve Director Kungahng Wang (atung Maca Memoral ostal) Pengu Wang (ae eterans eneral ostal) Hungsueh hou (hang ung Memoral ostal and hang ung nerst ollege o Medcne) nghang hang (hang ung Memoral ostal and hang ung nerst ollege o Medcne) Wen-Fang Cheng (Na�onal Taiwan University Collage of Medicine) MngShyen en (ae eterans eneral ostal) Drector Tang-Yuan Chu (Hualien Tzu Chi Hospital) Musen u (rSerce eneral ostal) Cheng-Yang Chou (Na�onal Cheng Kung University College of Medicine) Yaohng ung (hna Medcal nerst and hna Medcal nerst ostal) aeFang u (ae eterans eneral ostal) Keng-Fu Hsu (Na�onal Cheng Kung University College of Medicine) Bor-Ching Sheu (Na�onal Taiwan University Hospital) Yen hen (ae eterans eneral ostal) Pao-Ling Torng (Na�onal Taiwan University Hospital) haYen uang (atha eneral ostal) WenShung ou (aohsung eterans eneral ostal) FuShng u (Sho hwan Memoral ostal) Hung-Cheng Lai (Transla�onal Epigene�c Center, Shuang Ho Hospital) YuanYee an (uans eneral ostal) Execu�ve Supervisor anShung eh (hna Medcal nerst ollege o Medcne) Suersor uas Wu (ae eterans eneral ostal) ao n ( aohsung hang ung Memoral ostal) Soonen uang (h Me Medcal enter) An en hang (aohsung eterans eneral ostal) YaMn heng (ao eneral ostal) Chang-Yao Hsieh (Na�onal Taiwan University College of Medicine) Secretar eneral hhong hang (Maca Memoral ostal) ceSecretar eneral hensuan Wu (aohsung hang ung Memoral ostal) hensng u (achung eterans eneral ostal) YnY hang (hna Medcal nerst ostal) Tze-Ho Chen (Changhua Chris�an Hospital) Tze-Chien Chen (Mackay Memorial Hospital) Yu hen (Na�onal Taiwan University College of Medicine) 6 Floor Plan 張榮發基金會國際會議中心 6樓 配置圖僅供參考，攤位大小以實際尺寸為準 配置圖僅供參考，攤位大小以實際尺寸為準 張榮發基金會國際會議中心 6樓 601 VIP1 601 VIP2 VIP1 會議室 VIP2 大會報到處 大會報到處 點心區 點心區 學分簽到處 試片區 學分簽到處 603603 會議室會議室 A01 A01AZ AZ 610 A02 A03 A04 A05 A02羅氏 A03武田 A04東洋 A05百特 羅氏 武田 東洋 百特 7 Agenda Date: December 19th 2020 (Sat.) 601 Room Topic Speaker Moderator 0920092 enng remars o AS Presdent Dr. Dasue Ao 0920930 enng remars o S ce Presdent Dr. aeWeon m 0930093 enng remars o AGO Presdent Dr. hhMng o 093090 Time for Taiwan - My Beau�ful Island Prac�ce in gynecologic oncology during Covid 19 pandemics Korea Dr. Soom ang aan Dr. usue oayash 0901020 Dr. ungheng a nda Dr. eera hatla Malaysa Dr. Suresh umarasamy Taan Dr. henghang hang ovel mmunothera or adanced endometral cancer 1020100 Dr. haYen uang Dr. eeWen uang ( Industrial sec�on) date on cercal cancer surgery adomnal or 1001110 Dr. Se m Dr. ungiahng Wang mnmall nvase aroach 11101120 rea Update on treatment of metasta�c or relapsed 1120110 Dr. Paong orng Dr. WenFang heng cercal cancer adcal trachelectom or earl stage cercal 1101200 Dr. aau nomoto Dr. uas Wu cancer at 15-17 weeks of gesta�on 12001300 unch Anatomic dissec�on in nerve-sparing radical 13001320 Dr. Wuhou n Dr. ua hysterectom or cercal cancer Molecular characteriza�on and its clinical 1320130 Dr. nghang hang Dr. Shhhu o implica�on in endometrial cancer 130130 rea Two-step sen�nel lymph node mapping strategy 130110 Dr. SangWun m Dr. houhung uan n endometral cancer stagng Aduant thera or earl endometral cancer 110130 Dr. mo shma Dr. aMn heng hen and ho and hy? 8 601 Room Topic Speaker Moderator 13010 rea Treatment for stage 4 and metasta�c 10100 Dr. eeSeung m Dr. hyongue a endometral cancer 100120 Ovaran cancer surgery 1st and 2nd debulking opera�on Dr. Masa Manda Dr. ungsueh hou 120130 rea Personalized medicine- Maintenance therapy 13010 Dr. aYu se Dr. haYen uang n ovaran cancer 101610 Treatment or relased ovaran cancer Dr. engheng su Dr. Paong orng 16101620 rea urrent role o mnmall nvase surger or 1620160 Dr. en hen Dr. Pengu Wang ovaran cancer Big data analysis in popula�onal gynecologic 160100 Dr. heng ao Dr. WenShung ou oncolog methods and outcomes 100110 rea 110130 Shared decision-making in real prac�ce Dr. hensuan Wu Dr. ao n he th ASGO Biennial Mee�ng 13013 See ou n haland 9 Date: December 19th 2020 (Sat.) 603 Room Topic Speaker Moderator 0920092 enng remars o AS Presdent Dr. Dasue Ao 0920930 enng remars o S ce Presdent Dr. aeWeon m 0930093 enng remars o AGO Presdent Dr. hhMng o 093090 Time for Taiwan - My Beau�ful Island Prac�ce in gynecologic oncology during Covid 19 pandemics Korea Dr. Soom ang aan Dr. usue oayash 0901020 Dr. ungheng a nda Dr. eera hatla Malaysa Dr. Suresh umarasamy Taan Dr. henghang hang 1020100 Precson medcne n gnecologc cancers Dr. Shuen hen Dr. orhng Sheu Mechanism targe�ng homologous recombina�on 1001100 Dr. atsutosh DA Dr. Tze-Ho Chen deficiencies in ovarian cancer 11001110 rea 11101130 Biomarker and gene�c tes�ng for PARP inhibitor Dr. aMn heng Dr. MngShyen en Safety and QoL of Avas�n in Gyn cancer 11301200 Dr. ungsueh hou Dr. uMn e (Industrial sec�on) 12001230 S 10th Council mee�ng 12301300 TA 9th Council mee�ng Evolng area o mantenance thera n recurrent 13001330 Dr. ngheng hang Dr.
Load more

Recommended publications
  • Clitoridectomy, Excision, Infibulation- Female Circumcision Ritual and Its Consequences for Women's Health
    Rogala Dorota, Kornowska Joanna, Ziółkowska Mirosława. Clitoridectomy, excision, infibulation- female circumcision ritual and its consequences for women's health. Journal of Education, Health and Sport. 2018;8(11):583-593. eISNN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.2533136 http://ojs.ukw.edu.pl/index.php/johs/article/view/6451 https://pbn.nauka.gov.pl/sedno-webapp/works/896357 The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017). 1223 Journal of Education, Health and Sport eISSN 2391-8306 7 © The Authors 2018; This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 26.11.2018. Revised: 30.11.2018. Accepted: 30.11.2018. Clitoridectomy, excision, infibulation- female circumcision ritual and its consequences for women's health Dorota Rogala ¹, Joanna Kornowska 2, Mirosława Ziółkowska3 1 Department of Oncology, Radiotherapy and Gynecologic Oncology, Faculty of Health Sciences, Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland.
    [Show full text]
  • Embolization of Ruptured Ovarian Granulosa Cell Tumor Presenting As Acute Hemoperitoneum
    Published online: 2021-03-23 IR Snapshot Embolization of Ruptured Ovarian Granulosa Cell Tumor Presenting as Acute Hemoperitoneum A 56-year-old postmenopausal female peritoneal fluid with evidence of active Nasser Alhendi1,2, presented in shock state and abdominal contrast extravasation [Figure 1]. The exact Haitham Arabi2,3, distension. Contrast-enhanced computed origin of the mass could not be identified Raghad Alhindi1,4 tomography showed a large heterogeneous due to the presence of hemoperitoneum. 1Division of Vascular mass in the left adnexa surrounded by dense The patient was resuscitated with Interventional Radiology, Department of Medical Imaging, Ministry of National Guard‑Health Affairs, 2King Abdullah International Medical Research Center, 3Department of Pathology and Laboratory Medicine, Ministry of National Guard‑Health Affairs, 4Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia a b Figure 1: Axial pelvic contrast‑enhanced computed tomography scan in arterial phase (a) portal venous phase (b) large pedunculated heterogeneous mass arising from the uterine fundus/left adnexa, surrounded by extensive dense peritoneal fluid related to bleeding and showing internal contrast extravasation (white arrow) Address for correspondence: Dr. Nasser Alhendi, Department of Medical Imaging, Division of Vascular Interventional Radiology, King Abdulaziz Medical City, Riyadh, Saudi Arabia. E‑mail: dr_nasser1@hotmail. com Access this article online a b Website: www.arabjir.com Figure 2: Initial angiogram of left uterine artery demonstrates mildly hypertrophied distal branches (a) with focal DOI: 10.4103/AJIR.AJIR_42_18 contrast extravasation (a and b) (white arrows) Quick Response Code: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution- NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, How to cite this article: Alhendi N, Arabi H, as long as appropriate credit is given and the new creations Alhindi R.
    [Show full text]
  • Philippine Journal of Gynecologic Oncology – Volume 13 2016
    1 Diagnostic Accuracy of Intraoperative Frozen Section in the Diagnosis of Ovarian Neoplasms in a Tertiary Training Hospital: A 10-Year Retrospective Report* Jimmy A. Billod, MD, FPOGS, DSGOP, FPSCPC; Efren J. Domingo, MD, PhD, FPOGS, FSGOP, FPSCPC and Nelson T. Geraldino, MD, MPH, MBAH Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Philippine General Hospital, University of the Philippines Manila Objective: This study aimed to determine the concordance between frozen section and final paraffin histopathologic diagnoses and the performance rates of frozen section in terms of accuracy, sensitivity and specificity in the diagnosis of ovarian neoplasm in a tertiary training government hospital. Methodology: This is a retrospective validation study from 2004 -2013 involving 810 cases of ovarian neoplasms from gynecologic surgeries submitted for frozen section diagnosis. Records of all cases submitted for frozen section diagnosis pertaining to ovarian neoplasms were retrieved from the Surgical Pathology logbooks and computerized database. All histopathologic results of frozen and paraffin sections were retrieved and reviewed. In all the statistical tests, any associated p-values lesser than 0.05 alpha were considered significant. Results: The frozen section results such as benign, borderline, and malignant were associated with the final histopath results (p<0.001) with 89.09% agreement. The overall performance rates of frozen section for the 10-year period across the three categories were as follows, sensitivity of 81.8%, specificity of 99.2%, and overall accuracy rate of 92.9%. Size of the ovarian mass, gross character (cystic versus solid) , and epithelial histology particularly mucinous significantly lowered the accuracy rate (p <0.01).
    [Show full text]
  • 69292/2020/Estt-Ne Hr 5
    5 69292/2020/ESTT-NE_HR Index Sr. No. Particulars Page No. 1 General Billing Rules 2--11 2 Packages Detail 12--23 3 Room Rent 24--25 4 Consultation Charges. 26--32 5 CTVS PACKAGE ROCEDURES 33--35 6 CTVS PEDIATRIC 36--37 7 CATH ADULT PROCEDURES 38--39 8 EP STUDY PACKAGE PROCEDURES 40--41 9 PEDIATRIC CATH PROCEDURES 42--43 10 UROLOGY PROCEDURES 44--46 11 NEPHROLOGY PROCEDURES 47-52 12 VASCULAR SURGERY 53--54 13 GENERAL SURGERY PROCEDURE 55--62 14 NUEROLOGY PROCEDURES 63--67 15 UROLOGY 68--71 16 DENTAL PROCEDURES 72--78 17 DERMATALOGY PROCEDURES 79--82 18 ENT PROCEDURES 83--87 19 NEPHROLOGY 88--89 20 GYNECOLOGY PROCEDURES 90--93 21 LABORATORY TEST CHARGES 94-120 22 ONCOLOGY PROCEDURES 121-126 23 OPTHALMOLOGY PROCEDURES 127-130 24 PULMONOLOGY PROCEDURES 131-134 25 PAIN CLINIC CHARGES 135-136 26 PLASTIC SURGERY 137-141 27 PHYSIOTHERAPY CHARGES 142-144 28 MISC. & OTHER SERVICES 145-148 29 CARDIAC DIAGNOSTIC CHARGES 149-151 30 CT PROCEDURES 152-155 31 MRI PROCEDURES 156-162 32 X RAY PROCEDURES 163-166 33 ULTRASOUND PROCEDURES 167-169 34 DIAGNOSTIC NEUROLOGY 170-172 35 DIANG-HIS 173-174 36 BLOOD BANK 175-176 37 GASTROENTEROLOGY PACKAGES 177-178 38 GASTROENTEROLOGY 179-184 39 TRANSPLANT CHARGES 185-186 0 6 69292/2020/ESTT-NE_HR 40 ORTHOPAEDIC PACKAGES 187-189 41 ORTHOPAEDICS PROCEDURES 190-199 42 MAXILLOFACIAL SURGERY 200-206 43 ONCO SURGERY 207-209 44 INTERVENTIONAL RADIOLOGY & CARDIOLOGY 210-211 45 ANESTHESIA PROCEDURES 212-214 46 PSYCHOLOGY 215-216 1 7 69292/2020/ESTT-NE_HR GENERAL BILLING RULES & GUIDELINES 2 8 69292/2020/ESTT-NE_HR Registration and Admission Charges a) Onetime Registration charges of INR.100/- shall be charged to all new patients coming to Hospital for the first time.
    [Show full text]
  • Gynecologic Oncology
    Cancer: Gynecologic Oncology FirstHealth Oncology offers a board certified gynecologic oncologist for the evaluation and management of gynecological cancer. As part of the FirstHealth Outpatient Cancer Center a full range of services including education, support services, case management, symptom management and dietary services are available. Gynecologic Oncology Services Available • Management of gynecologic cancers to include ovarian, fallopian tube, Michael Sundborg, M.D. Brian Burgess, D.O. primary peritoneal carcinoma, uterine/endometrial, cervical, vulvar, and vaginal cancers • Advanced surgical management for complex pelvic disease • Administration and management of chemotherapy for gynecological malignancies • Long term surveillance for gynecological malignancies MI • Advanced minimally invasive surgery;DLAND Robotic Surgery RO • Palliative Supportive Care AIRPORT AD RO • Genetic counseling and managementAD for hereditary ovarian, breast and uterine cancers Adara Maness, PA-C • Management for suspected gynecological cancers to include pelvic masses • Management of gynecologic cancer patients via tumor board • Management of pre-invasive disease of the genital tract to include cervix, vulva and vagina MIDLAND RO • Management of gestational trophoblastic diseases to include persistent / invasive molar pregnancies,AD chorio carcinoma, placental site trophoblastic diseases E IEMORE DRIVE AV GE DRIV GE H ROAD SOUT PA PAGE N ROAD NORTH PAGE Main Phone Number: (910) 715-6740 Address: 35 Memorial Drive Entrance 4 Pinehurst, NC 28374 REGIONAL DRIVE LE RC AL DRIVE MEMORI REGIONAL CI E V I R D E G A L IL V T RS FI EPIC: REF 29 1 974-60-21 Cancer: Gynecologic Oncology To refer patients for a consult, call (910) 715-8684. Please give the patient a copy of this form to bring to his/her appointment.
    [Show full text]
  • Creating a New Paradigm in Gynecologic Cancer Care: Policy Proposals for Delivery, Quality and Reimbursement
    Creating a New Paradigm in Gynecologic Cancer Care: Policy Proposals for Delivery, Quality and Reimbursement A Society of Gynecologic Oncology White Paper February 2013 Creating a New Paradigm in Gynecologic Cancer Care February 2013 Table of Contents Executive Summary 3 I. Introduction 6 Purpose of the Report Key Questions II. What is the Society of Gynecologic Oncology? 7 III. Delivering High Quality Gynecologic Cancer Care 9 Weaknesses in Current Delivery Systems Proposed Solutions for Optimizing Delivery Systems Resources Needed to Implement the Care Team Model Ultimate Outcome of the Proposed Care Team Delivery Model IV. Defining High Quality Gynecologic Cancer Care 18 Weaknesses in Current Quality Systems Proposed Solutions and Resources Required to Optimize Quality Measures and Improvement What will be the Ultimate Outcome of this Proposed Quality Improvement System? V. Payment Systems for Delivery of High Quality 24 Gynecologic Cancer Care Weaknesses in Current Payment System Proposed Solutions to Optimize Payment Systems Resources Needed to Facilitate a Demonstration Project Followed by Implementation of New Payment Systems Resources Needed to Facilitate a Demonstration Project Followed by Implementation of New Payment Systems VI. Summary 35 References 37 Appendix 39 Practice Summit Participants 40 Page 2 Creating a New Paradigm in Gynecologic Cancer Care February 2013 Executive Summary The increasing financial burden of cancer care negatively impacts the U.S. health care system, our nation’s economy, and individuals’ quality of life. More importantly, it contributes significantly to premature death. The current health policy environment for cancer care is built upon a system that often rewards volume and intensity of therapy rather than proper coordination and quality of care.
    [Show full text]
  • Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due To
    Original Study Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due to Accelerated Follicle Loss in Turner Syndrome or Cancer Treatments K. Oktay MD 1,2,*, G. Bedoschi MD 1,2 1 Innovation Institute for Fertility Preservation and IVF, New York, NY 2 Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY abstract Objective: To preliminarily study the feasibility of oocyte cryopreservation in postpubertal girls aged between 13 and 15 years who were at risk for premature ovarian failure due to the accelerated follicle loss associated with Turner syndrome or cancer treatments. Design: Retrospective cohort and review of literature. Setting: Academic fertility preservation unit. Participants: Three girls diagnosed with Turner syndrome, 1 girl diagnosed with germ-cell tumor. and 1 girl diagnosed with lymphoblastic leukemia. Interventions: Assessment of ovarian reserve, ovarian stimulation, oocyte retrieval, in vitro maturation, and mature oocyte cryopreservation. Main Outcome Measure: Response to ovarian stimulation, number of mature oocytes cryopreserved and complications, if any. Results: Mean anti-mullerian€ hormone, baseline follical stimulating hormone, estradiol, and antral follicle counts were 1.30 Æ 0.39, 6.08 Æ 2.63, 41.39 Æ 24.68, 8.0 Æ 3.2; respectively. In Turner girls the ovarian reserve assessment indicated already diminished ovarian reserve. Ovarian stimulation and oocyte cryopreservation was successfully performed in all female children referred for fertility preser- vation. A range of 4-11 mature oocytes (mean 8.1 Æ 3.4) was cryopreserved without any complications. All girls tolerated the procedure well.
    [Show full text]
  • Wellness & Preventive Health
    wellness & preventive health Cancer treatments may increase your chance of developing other health problems years after you have completed treatment. The purpose of this self care plan is to inform you about what steps you can take to maintain good health after cancer treatment. Keep in mind that every person treated for cancer is different and that these recommendations are not intended to be a substitute for the advice of a doctor or other health care professional. Please use these recommendations to talk with your health care provider about an appropriate follow up care plan for you. Surveillance for Your Cancer Breast Cancer Screening Cancer surveillance visit with medical provider that is For more information, see the ACS document Breast focused on detecting signs of recurrence of your cancer. Cancer: Early Detection. For additional information, visit www.livestrong.org or www.cancer.org/cancer/breast-cancer/screening-tests-and- www.cancer.net/patient/Survivorship early-detection.html Frequency depends on type and stage of cancer you had. • Yearly mammograms starting at age 40-49, and (If you had a higher risk cancer, you may be seen more continuing yearly as long as a woman is in good health. often). Your doctor has provided you with a personalized • Clinical breast exam (CBE), performed by a health care cancer treatment summary and survivorship care plan. If professional, every 1-3 years for women aged 25-39, you need another copy, ask your doctor. and every year for women 40 and older. • A monthly breast self-exam (BSE) is a good way to General Cancer Screening for Women monitor breast health.
    [Show full text]
  • Rotation in Gynecologic Oncology
    Department of Obstetrics and Gynecology Externships for Visiting Medical Students Rotation in Gynecologic Oncology Externs choosing this elective rotation will function as student interns in the Division of Gynecologic Oncology. The Gynecologic Oncology Team cares for a diverse, multiethnic population of both county and private patients. The inpatient care takes place entirely on campus at Parkland Memorial Hospital and the William P. Clements Jr. University Hospital. The Gyn Onc Team consists of five faculty members, four gynecologic oncology fellows (two clinical and two laboratory fellows), and six Parkland residents. Externs will be integrated into this team to provide care for all women diagnosed with gynecologic malignancies at our institutions. During your time here, you will have both inpatient and outpatient experiences at Parkland Hospital as well as Clements University Hospital and the Harold C. Simmons Comprehensive Cancer Center. As an extern, you will scrub and assist in surgical cases and follow patients postoperatively. You will have a role in in-house consultations as well as medical admissions and will also have the opportunity to share your knowledge during daily ward rounds. Other tasks will include performing H&Ps on new clinic patients as well as seeing follow-up patients and learning chemotherapy options and side effects. You will also attend the resident didactic conferences and the gyn onc conferences. Our busy clinical service provides comprehensive clinical and surgical exposure for visiting students and offers the opportunity to learn about the diagnosis and treatment of gynecological cancers. This rotation is intended to provide an intense clinical experience with an emphasis on teaching.
    [Show full text]
  • Primary Melanoma of the Female Genital System: a Report of 10 Cases and Review of the Literature
    ANTICANCER RESEARCH 25: 1567-1574 (2005) Primary Melanoma of the Female Genital System: A Report of 10 Cases and Review of the Literature A. JAHNKE, J. MAKOVITZKY and V. BRIESE University of Rostock, Department of Obstetrics and Gynecology, Doberaner Strasse 142, 18057 Rostock, Germany Abstract. Background: Primary melanoma of the female malignancies. Although the biological behavior of vulvar genital system are extremely rare (2-3%). Patients and and vaginal melanoma is similar to cutaneus melanoma (5), Methods: A retrospective review was undertaken of patients the prognosis is very poor, as there is a high risk of local with primary melanoma of the female genital system treated progression as well as distant metastases. Malignant from 1990-2003 at Rostock University Hospital, Germany. melanoma can form metastases primarily in the skin, tissue, Different treatments (sentinel node biopsy, inguinofemoral the lymph nodes and the lung ("limited disease") as well as lymphadenectomy, en bloc resection, adjuvant Interferon- in other organ systems (visceral, ossary and cerebral system: alpha-therapy, adjuvant chemotherapy) are discussed. The "extensive disease") (6). If there is a minimal suspicion of complicated classification is reduced to a clinical path for daily melanotic change, the affected area has to be removed use (UICC stage and invasion depth of Breslow, Clark’s level completely and to be examined (immuno-) histo- and Chung’s level). Results: We report on 10 patients, aged 26 pathologically (Vimentin, S-100-Protein, HMB45). Different to 76 years, with primary melanoma of the female genital tract. types of melanoma can be categorized according to clinical Seven women developed a vulvar melanoma and one woman and histological parameters: superficially spreading a malignant melanoma of the cutaneous inguinal region, while melanoma (SSM), nodular melanoma (NM), acral another 2 women had an unusual primary location of the lentiginous melanoma (ALM) and lentigo-maligna- malignant melanoma, the cervico-vaginal region (n=1) and melanoma (LMM).
    [Show full text]
  • Primary Vaginal Malignant Melanoma: a Case Report and Review of Literature
    Open Access Case Report DOI: 10.7759/cureus.10536 Primary Vaginal Malignant Melanoma: A Case Report and Review of Literature Mahati Paravathaneni 1 , Vinay Edlukudige Keshava 1 , Bohdan Baralo 1 , Rajesh Thirumaran 2 1. Internal Medicine, Mercy Catholic Medical Center, Darby, USA 2. Hematology/Oncology, Mercy Catholic Medical Center, Darby, USA Corresponding author: Mahati Paravathaneni, [email protected] Abstract Primary vaginal malignant melanoma is an extremely rare and aggressive tumor with very few reported cases worldwide. It often occurs in post-menopausal women, with a mean age of 57 years. The most common presenting symptom is vaginal bleeding. Other less common presenting symptoms are vaginal discharge, vaginal mass, and pain. Vaginal melanomas are often diagnosed at an advanced stage, and despite the aggressive treatment approach, the prognosis is poor. We present to you a case of a 56-year-old post- menopausal woman who presented with intermittent vaginal bleeding and passage of dark clots. She was found to have symptomatic anemia requiring blood transfusions. Further workup revealed a mass in the upper vagina on imaging studies, and the patient eventually underwent a biopsy, which confirmed the diagnosis of malignant melanoma of the vagina on pathological examination. Categories: Internal Medicine, Obstetrics/Gynecology, Oncology Keywords: vaginal bleeding, postmenopausal, vaginal cancer, malignant melanoma Introduction Primary vaginal malignant melanoma is an infrequent entity, with less than 250-300 cases reported in the literature, accounting for only 0.46 cases per million women per year [1,2]. The etiology of melanoma of the female genitourinary tract, in general, has not been understood fully. However, it seems to be evident that ultraviolet radiation exposure is not a causative factor, in contrast to cutaneous malignant melanoma, given the areas are less exposed.
    [Show full text]
  • Vaginal Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis
    cancer.org | 1.800.227.2345 Vaginal Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Finding cancer early, when it's small and hasn't spread, often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that's not always the case. ● Can Vaginal Cancer Be Found Early? ● Signs and Symptoms of Vaginal Cancer ● Tests for Vaginal Cancer Stages and Outlook (Prognosis) After cancer is diagnosed, staging provides important information about the amount of cancer in the body and the likely response to treatment. ● Vaginal Cancer Stages ● Survival Rates for Vaginal Cancer Questions to Ask About Vaginal Cancer Here are some questions you can ask your cancer care team to help you better understand your cancer diagnosis and treatment options. ● Questions to Ask Your Doctor About Vaginal Cancer 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Can Vaginal Cancer Be Found Early? Sometimes vaginal cancer can be found early, when it's small and hasn't spread. It can cause symptoms that lead women to seek medical attention. But many vaginal cancers don't cause symptoms until they've grown and spread. Pre-cancerous areas of vaginal intraepithelial neoplasia (VAIN) don't usually cause any symptoms. Still, routine ob-gyn exams and cervical cancer screening1 can sometimes find cases of VAIN and early invasive vaginal cancer. Hyperlinks 1. www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/detection.html References American Society of Clinical Oncology. Vaginal Cancer: Risk Factors and Prevention. 08/2017. Accessed at www.cancer.net/cancer-types/vaginal-cancer/risk-factors-and- prevention on March 7, 2018.
    [Show full text]